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Vasopressor agents may affect cerebral oxygenation (rScO2) as determined by
near-infrared spectroscopy on the forehead. This case series evaluated the effect of
calcium chloride vs. α and β-adrenergic receptor agonists on rScO2 in patients (n = 47)
undergoing surgery during i.v. anesthesia. Mean arterial pressure (MAP) and cardiac
output (CO) were assessed by Model-flow® and ephedrine (55 ± 3 vs. 74 ± 9mmHg;
10mg, n = 9), phenylephrine (51 ± 5 vs. 78 ± 9mmHg, 0.1mg, n = 11), adrenaline (53 ± 3
vs. 72 ± 11mmHg; 1–2μg, n = 6), noradrenaline (53 ± 5 vs. 72 ± 12mmHg; 2–4μg, n =
11), and calcium chloride (49 ± 7 vs. 57 ± 16mmHg; 5mmol, n = 10) increased MAP (all
P < 0.05). CO increased with ephedrine (4.3 ± 0.9 vs. 5.3 ± 1.2, P < 0.05) and adrenaline
(4.7 ± 1.2 vs. 5.9 ± 1.1 l/min; P = 0.07) but was not significantly affected by phenylephrine
(3.9 ± 0.7 vs. 3.6 ± 1.0 l/min), noradrenaline (3.8 ± 1.2 vs. 3.7 ± 0.7 l/min), or calcium
chloride (4.0 ± 1.4 vs. 4.1 ± 1.5 l/min). Following administration of β-adrenergic agents
and calcium chloride rScO2 was preserved while after administration of α-adrenergic
drugs rScO2 was reduced by app. 2% (P < 0.05). Following α-adrenergic drugs to
treat anesthesia-induced hypotension tissue oxygenation is reduced while the use of
β-adrenergic agonists and calcium chloride preserve tissue oxygenation.
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INTRODUCTION
Cerebral autoregulation has a lower limit (Paulson et al., 1990)
and following induction of anesthesia blood pressure may
decrease to what is considered to be below that level. Accordingly,
patients receive intravenous administration of vasopressor agents
such as phenylephrine (an α-adrenergic receptor agonist) or
ephedrine that stimulates both α- and β-adrenergic recep-
tors. Bolus calcium chloride could also increase blood pressure
(Ellender and Skinner, 2008) by an increase in intracellular cal-
cium to increase cardiac stroke volume via an effect on myocytes
and vascular resistance via increased contraction of smooth mus-
cles. Also calcium chloridemay increase venous return by unload-
ing the splanchnic reservoir. Thus, with administration of calcium
chloride cardiac output (CO) increases without affecting heart
rate (HR) (Ellender and Skinner, 2008) contrasting ephedrine
that has the potential to increase both HR and CO.
Phenylephrine decreases the near infrared spectroscopy
(NIRS) determined frontal lobe oxygenation (rScO2) (Brassard
et al., 2010, 2014; Nissen et al., 2010; Meng et al., 2011; Foss
et al., 2014) related to vasoconstriction in extracranial vascu-
lature rather than to a decrease in cerebral oxygenation (Ogoh
et al., 2011, 2014; Sørensen et al., 2012). In this study patients
undergoing major abdominal surgery were recruited to evalu-
ate rScO2 following routine administration of vasoactive drugs
to treat a drop in blood pressure by induction of anesthesia. We
used bolus calcium chloride along with the vasopressor agents
phenylephrine, ephedrine, adrenaline or noradrenaline depend-
ing on the choice of the anesthesiologist. We tested the hypothesis
that administration of ephedrine, adrenaline and calcium chlo-
ride to treat anesthesia-induced hypotension would preserve
rScO2, while rScO2 would be reduced following administration of
drugs that stimulate α-adrenergic receptors (phenylephrine and
noradrenaline).
METHODS
In a pilot-like prospective study-design as approved by the
regional ethical committee (H-1-2009-107) we included predom-
inantly patients planned for major abdominal surgery. In 47
patients (age 63± 7 yrs, height 176± 7 cm, weight 78± 16 kg; 28
males; mean ± SD) this selection of cases tested the effect of dif-
ferent vasopressor agents on anesthesia-induced hypotension and
rScO2. Most patients were admitted for planned surgery includ-
ing the liver, pancreas, esophagus, ventricle, or colon. In one case
the spleen was the target for surgery and an other patient suffered
from a retroperitoneal tumor. Three patients underwent vascu-
lar surgery and one patient was in surgery for hydronephrosis.
Diabetes requiring insulin and the use of anti-hypertensive med-
ication were considered to contradict inclusion in the evaluated
series of patients. An increase in bilirubin was also an exclusion
criterion due to the influence of bilirubin on near-infrared light
absorption (Madsen et al., 2000).
The patients were exposed to at least 6 h of fast and orally
intake of clear fluids was stopped 2 h before surgery. Three-lead
electrocardiography monitored HR and pulse oximetry assessed
arterial hemoglobin O2 saturation (SpO2). A hand vein was
used for administration of fluid and anesthetics. According to
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local guidelines, a radial artery catheter (20 gage; 1.1mm) was,
after local anesthesia, inserted in the arm with the highest non-
invasively determined systolic blood pressure and the catheter
was kept patent by isotonic saline (3ml/h) through to a trans-
ducer (Edwards Life Sciences, Irving, CA, USA) positioned at the
level of the heart. For surgery an epidural catheter was placed at
Th. 8–10 in the lateral decubitus position and under local anes-
thesia, lidocaine (3ml, 10mg/ml) with adrenaline (5μg/ml) was
administered to test for intravascular or intrathecal placement.
A two channel cerebral oximeter (INVOS 5100C, Somanetics,
Troy, MI, USA) detected rScO2 that represents hemoglobin oxy-
gen saturation in the tissue beneath the sensor as the ratio
between oxygenated and total hemoglobin. As approved by the
US Food and Drug Administration (510k-080769), the INVOS
5100C-determined rScO2 is considered a trend monitor of the
hemoglobin O2 saturation for skin, scalp, and cortical tissue.
With the NIRS-probe applied on the forehead it is assumed that
capillaries within the frontal lobe contribute to light absorbance
(Madsen and Secher, 1999) but skin, subcutaneous tissue and the
scalp blood flow also influences the INVOS-determined rScO2
(Davie and Grocott, 2012). rScO2 was determined at least 2 cm
above the eyebrows to limit an influence from the frontal sinus
on rScO2 (Tubbs et al., 2002). Cardiovascular variables including
mean arterial pressure (MAP), HR, cardiac stroke volume (SV)
and thus CO were assessed invasively by Model-flow® (Nexfin,
B.V, Amsterdam, The Netherlands; Bogert and van Lieshout,
2005).
Anesthesia was induced with propofol (2mg/kg) and main-
tained with propofol (0.08mg/kg/min) and remifentanil (0.3–
0.4μg/kg/min). For ventilation a Dräger CATO (M32040,
Lübeck, Germany) in volume-controlled mode was adjusted to an
end-tidal CO2 tension of 4–4.5 kPa and a positive end-expiratory
pressure of 5 cm H2O was used. When the patient was orally
intubated, the inspiratory O2 fraction was set to 0.7 to pre-
serve rScO2 (Rokamp et al., 2014). From induction of anesthe-
sia, including tracheal intubation and until surgical incision, a
reduction in MAP to below 60mmHg was treated with adminis-
tration calcium chloride (5mmol) or α- and β adrenergic recep-
tors: ephedrine (10mg), phenylephrine (0.1–0.2mg), adrenaline
(1–2μg), or noradrenaline (2–4μg). No patient received more
than one vasoactive agent.
It was estimated that to demonstrate a 10 ± 1.5% change in
rScO2 (from 70% to 63%) as compared to the level before admin-
istration of the drug (alpha 0.05, power >90%) 17 patients was
needed in each group. The goal was set to 20 patients to take
drop-outs into account, but due to slow enrolment in study it was
terminated. The study was conducted as open-label as the drug
used depended on the choice of the anesthesiologist.
For comparison of values before and after drug administra-
tion a paired t-test (two tailed) was used and for comparison
between groups and a t-test for unpaired data. For evaluation
of differences in age, height and weight between groups we used
ANOVA with unpaired data and a Tukey-test for post-hoc analy-
sis. Analysis was performed by statistical software (PRISM 6.0 for
MacOS; GraphPad software, San Diego, CA, USA) and a P < 0.05
was considered statistically significant.
RESULTS
Nine patients were provided with ephedrine to correct anesthesia-
induced hypotension, phenylephrine was administered to eleven
patients, noradrenaline to eleven patients, six patients received
adrenaline, and calcium chloride was administered to ten
patients. The five groups of patients were comparable in terms of
height and weight but the patients in the adrenaline group were
younger than those in the other groups (Table 1).
Bolus calcium chloride maintained HR, SV, and CO and,
as intended MAP increased (from 49 ± 7 to 57 ± 16mmHg,
P < 0.05) (Table 2, Figure 1). The other vasoactive agents also
influenced cardiovascular variables: following administration of
adrenaline SV tended to increase (P = 0.08) and as HR was
maintained (P = 0.71) also CO tended to increase (by 25%,
P = 0.07). Similarly, administration of ephedrine increased CO
(P < 0.05) due to a non-significant change in HR (P = 0.26)
and SV (P = 0.10). Both adrenaline and ephedrine increased
MAP by 19mmHg. Phenylephrine and noradrenaline maintained
HR, SV, and CO with an increase in MAP by 27 and 20mmHg,
respectively.
The effect of vasoactive therapy on the NIRS determined
rScO2 are shown in Table 2 and Figure 1. In patients treated
with adrenaline and ephedrine rScO2 was not affected sig-
nificantly and when these data were pooled into one group
of patients treated with β-adrenergic drugs, rScO2 remained
statistical unaffected: there was an increase in rScO2 for five
patients and for seven patients rScO2 decreased without relation
to changes in MAP or CO. After noradrenaline and phenyle-
phrine a small but non-significant reduction in rScO2 was
noted for each vasoactive agent. However, with data evaluated
as one group (α-adrenergic receptor agonists; noradrenaline and
phenylephrine), seven patients with noradrenaline and seven
patients with phenylephrine demonstrated lowered rScO2 after
drug administration while for only six patients rScO2 increased
(Figure 2). For two of these patients rScO2 decreased almost 10%
Table 1 | Patient characteristics in five groups of patients who received vasoactive therapy to treat anesthesia-induced hypotension.
Ephedrine Adrenaline Phenylephrine Noradrenaline Calcium chloride
(n = 9) (n = 6) (n = 11) (n = 11) (n = 10)
Age (yrs) 67±3 56±11* 64±7 64±3 60± 9
Weight (kg) 84±18 76±13 76±9 76±16 80± 22
Height (cm) 178±5 174±6 179±7 177±7 172± 7
Variable are mean ± SD. *Difference between Ephedrine and Adrenaline; P < 0.05.
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Table 2 | Cardiovascular variables in five groups of vasoactive therapy to treat anesthesia-induced hypotension.
Adrenaline After Ephedrine After Noradrenaline After Phenylephrine After Calcium After
before before before before before
HR (beat/min) 65±5 63±9 60±9 64±18 57±18 58±19 56±11 55±12 61±14 58± 15
SV (ml) 72±17 89±10* 76±14 82±15* 64±14 70±12 66±9 67±11 65±21 67± 17
CO (L/min) 4.7±1.1 5.9±1.1* 4.3±0.9 5.3±1.2* 3.8±1.2 3.7±0.7 3.9±0.7 3.6±1.0 4.0±1.4 4.1± 1.5
MAP (mmHg) 53±3 72±11* 55±3 74±9* 53±5 72±12* 51±5 78±9* 49±7 57± 16*
rScO2 (%) 58±13 58±12 73±10 73±11 70±12 68±11 67±8 66±7 68±12 68± 11
Variables are mean ± SD. HR, heart rate; SV, cardiac stroke volume; CO, cardiac output; MAP, mean arterial pressure; rScO2, frontal lobe oxygenation. *Different
between before and after in each group; P < 0.05. In calcium group determination of CO and SV was successful in six patients. After adrenaline SV and CO changed


























FIGURE 1 | Frontal lobe oxygenation (rScO2) in response to α- or
β-adrenergic agents or to calcium chloride (lower panel) to treat
anesthesia-induced hypotension in surgical patients. ∗Different from
baseline; P < 0.05.
while CO increased (0.5 and 2.3 L/min) and for the whole group
of patients (α-adrenergic receptor agonists) rScO2 decreased 2%.
After calcium chloride in four patients rScO2 decreased (1–5%)
and while rScO2 was unchanged (n = 2) or increased (up to 6%)
in the other eight patients, rScO2 was not statistical affected by
calcium chloride. Correlations between rScO2 and MAP or CO
were not observed.
DISCUSSION
This case series of 47 patients confirms that following anesthesia-
























FIGURE 2 | Effects of α- or β-adrenergic agents on cardiac output
following anesthesia in surgical patients. ∗Different from baseline; †,
difference between groups. P < 0.05.
agent including calcium chloride increases MAP. The new find-
ing is that frontal lobe oxygenation (rScO2), as determined by
near-infrared spectroscopy was not significantly affected follow-
ing the use of calcium chloride for treatment of anesthesia-
induced hypotension. A similar finding was observed with the
use of ephedrine, phenylephrine, adrenaline, and noradrenaline
as rScO2 remained at levels similar to those established before
drug administration. However, when data from patients treated
with α-adrenergic receptor agonists (phenylephrine and nora-
drenaline) were pooled into one group and patients treated with
β-adrenergic drugs (adrenaline or ephedrine) were sampled in
an other group, rScO2 decreased 2% after α-adrenergic drug
administration but remained unaffected with administration of
β-adrenergic stimulating drugs. This observation supports results
obtained in patients (Nissen et al., 2010; Meng et al., 2011;
Brassard et al., 2014) and healthy awake subjects (Brassard et al.,
2010). Although a 2% reduction in rScO2 seems small, the change
is in the magnitude as induced by hyperventilation that lowers
arterial CO2 partial pressure with development of presyncopal
symptoms (Madsen and Secher, 1999). Also Thomas et al. (2009)
report ∼6% drop in cerebral oxygenation at presyncope.
Why rScO2 is reduced after α-adrenergic drugs and not after
administration of β-adrenergic-therapy and calcium chloride
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remains unclear. In patients with intact cerebral autoregula-
tion, the decrease in rScO2 after phenylephrine and noradrenalin
administration is associated with concordant reduction in
CO, whereas rScO2 remains unchanged when CO was main-
tained with ephedrine (Meng et al., 2011). This observa-
tion supports that changes in CO, independently of arterial
pressure, affect cerebral hemodynamics (Ogoh et al., 2005).
Cerebral arteries are abundantly innervated by sympathetic
fibers (Sandor, 1999) and the decrease in rScO2 after admin-
istration of α-adrenergic drugs could be by direct α-receptor-
mediated cerebral vasoconstriction. An influence of cutaneous
vasoconstriction beneath the NIRS optode, however has to
be considered (Davie and Grocott, 2012; Sørensen et al.,
2012).
The increase in MAP by vasoactive therapy was expected
and the use of bolus calcium chloride also increased MAP even
in patients without a suspected reduction in plasma ionized
calcium. Indication for the use of calcium chloride is more
clear after the use of blood products containing citrate that
may lead to hypocalcemia (Jawan et al., 2003) and hemody-
namic instability (Marquez et al., 1986). Thus, calcium chloride
restores the levels of ionized calcium in blood and in turn
also MAP.
Despite the effect of vasoactive agents on MAP was similar
with the use of different drugs, the rise in pressure was achieved
differently. Both ephedrine and adrenaline increased CO but
such an effect was absent after administration of phenylephrine
or noradrenaline. When data from patients treated with nora-
drenaline and phenylephrine were pooled into one group, COwas
reduced in several patients (Figure 2): the eight lowest points with
a decrease in CO by up to app. 50% represent four patients treated
with phenylephrine and four patients treated with noradrenaline.
After calcium chloride CO was unchanged and there was a trend
towards a reducedHR (P = 0.16). Formost of the patients treated
with β-adrenergic agonists, CO increases by unloading of the
splanchnic reservoir (Cannesson et al., 2012). An increase in CO
may be important to override potential vasoconstriction in cuta-
neous and subcutaneous vessels following the use of vasoactive
therapy. Considering that microvascular circulation influences
wound healing, we consider that vasoactive drugs with significant
vasoconstrictive capacity should be avoided both during and after
surgery.
The use of calcium chloride to restore MAP is safe and in
terms of the effect on rScO2 this study is unable to promote
one vasoactive drug over an other. The data do suggest that the
use of a vasopressor agent with combined α- and β-adrenergic
agonistic capacity appears to be favorable to restore MAP follow-
ing anesthesia-induced hypotension. Results from a randomized
double-blinded clinical trial are needed before a general recom-
mendation to use combined α- and β-adrenergic drugs or cal-
cium chloride for treatment of anesthesia-induced hypotension is
substantiated.
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